Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-140-5p ABCC9 0.84 4.0E-5 -2.76 0 miRanda -0.19 0.04837 NA
2 hsa-miR-152-3p ABCD3 -0.05 0.84435 0.14 0.52609 MirTarget -0.18 9.0E-5 NA
3 hsa-miR-140-5p ABLIM1 0.84 4.0E-5 -1.72 0 PITA; miRanda -0.24 0.00036 NA
4 hsa-miR-140-5p ACACA 0.84 4.0E-5 -0.16 0.29248 miRanda -0.17 0 NA
5 hsa-miR-34a-5p ACSL4 1.9 0 -0.41 0.0792 miRNAWalker2 validate; MirTarget; miRNATAP -0.13 0.00399 NA
6 hsa-miR-194-5p ACTR3 1.9 0 -0.05 0.71644 mirMAP -0.11 0 NA
7 hsa-miR-140-5p ADAM10 0.84 4.0E-5 0.67 0.00766 MirTarget; PITA; miRanda -0.12 0.04176 NA
8 hsa-miR-34a-5p ADAM22 1.9 0 -1.12 0.02589 MirTarget; miRNATAP -0.32 0.00075 NA
9 hsa-miR-140-5p ADAM9 0.84 4.0E-5 -0.2 0.40665 PITA; miRanda; miRNATAP -0.21 0.00023 NA
10 hsa-miR-152-3p ADAMTS19 -0.05 0.84435 -2.99 0 MirTarget -0.65 0 NA
11 hsa-miR-34a-5p ADAMTS2 1.9 0 -0.77 0.15763 MirTarget -0.53 0 NA
12 hsa-miR-194-5p ADAMTS5 1.9 0 -2.16 0 mirMAP -0.26 0 NA
13 hsa-miR-34a-5p ADARB1 1.9 0 -1.93 0 miRNAWalker2 validate -0.48 0 NA
14 hsa-miR-34a-5p AFAP1L2 1.9 0 0.06 0.85809 miRNAWalker2 validate -0.18 0.00406 NA
15 hsa-miR-34a-5p AFF4 1.9 0 -0.82 0 miRNATAP -0.11 0.00024 NA
16 hsa-miR-140-5p AGAP1 0.84 4.0E-5 -0.4 0.01021 miRanda -0.12 0.00085 NA
17 hsa-miR-34a-5p AHNAK 1.9 0 -1.66 0 miRNAWalker2 validate -0.3 0 NA
18 hsa-miR-140-5p AKAP11 0.84 4.0E-5 -0.8 0 MirTarget; miRanda -0.18 1.0E-5 NA
19 hsa-miR-140-5p AKAP13 0.84 4.0E-5 -1.15 0 miRanda -0.16 1.0E-5 NA
20 hsa-miR-34a-5p AKAP13 1.9 0 -1.15 0 mirMAP -0.21 0 NA
21 hsa-miR-140-5p AKAP6 0.84 4.0E-5 -3.34 0 miRanda -0.44 3.0E-5 NA
22 hsa-miR-34a-5p AKAP6 1.9 0 -3.34 0 MirTarget -0.91 0 NA
23 hsa-miR-152-3p AKAP7 -0.05 0.84435 -1.26 1.0E-5 MirTarget -0.18 0.00129 NA
24 hsa-miR-34a-5p ALCAM 1.9 0 -0.73 0.05647 MirTarget; miRNATAP -0.18 0.01418 NA
25 hsa-miR-194-5p ALDH1L2 1.9 0 -1.12 0.02448 mirMAP -0.62 0 NA
26 hsa-miR-34a-5p ALDH1L2 1.9 0 -1.12 0.02448 MirTarget -0.67 0 NA
27 hsa-miR-34a-5p AMOTL2 1.9 0 -1.01 0.00015 MirTarget -0.31 0 NA
28 hsa-miR-194-5p ANGPTL1 1.9 0 -4.51 0 MirTarget -0.72 0 NA
29 hsa-miR-34a-5p ANK2 1.9 0 -4.32 0 MirTarget; miRNATAP -0.92 0 NA
30 hsa-miR-140-5p ANK3 0.84 4.0E-5 -0.29 0.31896 miRanda -0.2 0.00341 NA
31 hsa-miR-140-5p ANKRD12 0.84 4.0E-5 -0.64 0.00012 miRanda -0.13 0.00079 NA
32 hsa-miR-140-5p ANKRD17 0.84 4.0E-5 -0.09 0.56547 miRanda -0.12 0.00072 NA
33 hsa-miR-140-5p ANKRD34A 0.84 4.0E-5 -0.41 0.07282 miRanda -0.15 0.00586 NA
34 hsa-miR-140-5p ANKS1B 0.84 4.0E-5 -3.65 0 miRanda -0.26 0.03078 NA
35 hsa-miR-140-5p ANO6 0.84 4.0E-5 -0.74 3.0E-5 miRanda -0.17 7.0E-5 NA
36 hsa-miR-34a-5p ANP32B 1.9 0 0.07 0.67073 miRNATAP -0.12 7.0E-5 NA
37 hsa-miR-34a-5p AP1S2 1.9 0 -1.31 0 MirTarget -0.43 0 NA
38 hsa-miR-34a-5p AR 1.9 0 -3.3 0 MirTarget -0.29 0.02683 24349627; 22347519; 21343391; 25920548; 25797256; 23145211 In this study we found loss of miR-34a which targets AR in PCa tissue specimens especially in patients with higher Gleason grade tumors consistent with increased expression of AR; Most importantly BR-DIM intervention in PCa patients prior to radical prostatectomy showed reexpression of miR-34a which was consistent with decreased expression of AR PSA and Notch-1 in PCa tissue specimens; PCa cells treated with BR-DIM and 5-aza-dC resulted in the demethylation of miR-34a promoter concomitant with inhibition of AR and PSA expression in LNCaP and C4-2B cells; These results suggest for the first time epigenetic silencing of miR-34a in PCa which could be reversed by BR-DIM treatment and thus BR-DIM could be useful for the inactivation of AR in the treatment of PCa.This corrects the article on p;In this study we found loss of miR-34a which targets AR in PCa tissue specimens especially in patients with higher Gleason grade tumors consistent with increased expression of AR; Most importantly BR-DIM intervention in PCa patients prior to radical prostatectomy showed re-expression of miR-34a which was consistent with decreased expression of AR PSA and Notch-1 in PCa tissue specimens; PCa cells treated with BR-DIM and 5-aza-dC resulted in the demethylation of miR-34a promoter concomitant with inhibition of AR and PSA expression in LNCaP and C4-2B cells;In particular analysis of clinical prostate cancers confirmed a negative correlation of miR-34a and miR-34c expression with AR levels;To explore further the possible role of miRNAs in the AR pathway LNCaP cell line was treated with 5α-dihydrotestosterone and flutamide showing alteration in miRNAs expression especially miR-34a which was significantly underexpressed after treatment with high doses of 5α-dihydrotestosterone; Our data support a role for miRNAs especially miR-371 and miR-34a in the complex disarrangement of AR signaling pathway and in the behavior of PC;Repression of miR-34a a known AR-targeting miRNA contributes AR expression by XRN1;Inactivation of AR and Notch 1 signaling by miR 34a attenuates prostate cancer aggressiveness; We found that over-expression of miR-34a led to reduced expression of AR PSA and Notch-1; These findings suggest that the loss of miR-34a is directly linked with up-regulation of AR and Notch-1 both of which are highly expressed in PCa and thus finding innovative approaches by which miR-34a expression could be up-regulated will have a huge impact on the treatment of PCa especially for the treatment of mCRPC
39 hsa-miR-34a-5p ARHGAP1 1.9 0 -0.88 0 miRNAWalker2 validate; MirTarget; miRNATAP -0.18 0 NA
40 hsa-miR-194-5p ARHGAP21 1.9 0 -0.23 0.20424 MirTarget; miRNATAP -0.13 0 NA
41 hsa-miR-194-5p ARHGAP24 1.9 0 -2.02 0 miRNATAP -0.46 0 NA
42 hsa-miR-140-5p ARHGAP32 0.84 4.0E-5 0.68 0.00492 miRanda -0.16 0.00502 NA
43 hsa-miR-140-5p ARHGEF4 0.84 4.0E-5 -1.44 0.0131 miRanda -0.48 0.00046 NA
44 hsa-miR-140-5p ARIH1 0.84 4.0E-5 -0.41 0.00018 MirTarget; miRanda -0.12 1.0E-5 NA
45 hsa-miR-152-3p ARL6IP1 -0.05 0.84435 0.96 0 MirTarget -0.14 5.0E-5 NA
46 hsa-miR-140-5p ARMC9 0.84 4.0E-5 -0.17 0.43502 miRanda -0.13 0.01514 NA
47 hsa-miR-140-5p ARSK 0.84 4.0E-5 -0.17 0.31336 miRanda -0.1 0.01056 NA
48 hsa-miR-194-5p ASAP1 1.9 0 0.06 0.77944 MirTarget; miRNATAP -0.11 0.00108 NA
49 hsa-miR-34a-5p ASB1 1.9 0 -0.87 0 MirTarget; miRNATAP -0.16 0 NA
50 hsa-miR-140-5p ASB5 0.84 4.0E-5 -6.18 0 miRanda -0.99 0 NA
51 hsa-miR-140-5p ASH1L 0.84 4.0E-5 -0.67 0.00016 miRanda -0.26 0 NA
52 hsa-miR-34a-5p ASTN1 1.9 0 -2.34 2.0E-5 MirTarget -0.25 0.01797 NA
53 hsa-miR-140-5p ASXL2 0.84 4.0E-5 -0.51 0.09339 mirMAP -0.16 0.02429 NA
54 hsa-miR-34a-5p ASXL2 1.9 0 -0.51 0.09339 MirTarget -0.27 0 NA
55 hsa-miR-194-5p ATE1 1.9 0 -1.09 3.0E-5 MirTarget -0.1 0.0104 NA
56 hsa-miR-194-5p ATF2 1.9 0 -0.36 0.09137 miRNATAP -0.11 0.00127 NA
57 hsa-miR-194-5p ATL3 1.9 0 -0.19 0.4343 MirTarget -0.21 0 NA
58 hsa-miR-194-5p ATP8B4 1.9 0 -1.9 0 MirTarget -0.42 0 NA
59 hsa-miR-140-5p ATP9B 0.84 4.0E-5 -0.61 3.0E-5 miRanda -0.1 0.00301 NA
60 hsa-miR-34a-5p AXIN2 1.9 0 -1.7 6.0E-5 miRNAWalker2 validate; miRTarBase -0.32 9.0E-5 23624843 p53 regulates nuclear GSK 3 levels through miR 34 mediated Axin2 suppression in colorectal cancer cells; Exogenous miR-34a decreases Axin2 UTR-reporter activity through multiple binding sites within the 5' and 3' UTR of Axin2; Further RNA transcripts of miR-34 target were correlated with Axin2 in clinical data set of colorectal cancer patients
61 hsa-miR-34a-5p AXL 1.9 0 -1.77 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.54 0 26667302; 21814748; 25895459 Negative feedback regulation of AXL by miR 34a modulates apoptosis in lung cancer cells; To clarify the role of miRNAs in this regulation loop approaches using bioinformatics and molecular techniques were applied revealing that miR-34a may target the 3' UTR of AXL mRNA to inhibit AXL expression; Therefore we propose that AXL is autoregulated by miR-34a in a feedback loop; this may provide a novel opportunity for developing AXL-targeted anticancer therapies;We identified human miR-34a expression as being >3-fold down from its median expression value across all cell lines in MDA-MB-231 cells and identified AXL as a putative mRNA target using multiple miRNA/target prediction algorithms; In reporter assays miR-34a binds to its putative target site within the AXL 3'UTR to inhibit luciferase expression; Finally we present an inverse correlative trend in miR-34a and AXL expression for both cell line and patient tumor samples;MiR 34a suppresses ovarian cancer proliferation and motility by targeting AXL; Overexpression of miR-34a led to the inhibition of AXL expression indicating that AXL is a target gene for miR-34a; Our data suggest that miR-34a may function as a tumor suppressor through repression of oncogenic AXL in ovarian cancer
62 hsa-miR-140-5p BAG4 0.84 4.0E-5 0.14 0.55811 miRanda -0.16 0.00409 NA
63 hsa-miR-140-5p BAZ2B 0.84 4.0E-5 -0.74 3.0E-5 PITA; miRanda; miRNATAP -0.27 0 NA
64 hsa-miR-140-5p BBS4 0.84 4.0E-5 0.02 0.87409 miRanda -0.13 4.0E-5 NA
65 hsa-miR-140-5p BBS9 0.84 4.0E-5 -0.33 0.02266 miRanda -0.14 3.0E-5 NA
66 hsa-miR-140-5p BCHE 0.84 4.0E-5 -4.37 0 miRanda -0.52 0.00051 NA
67 hsa-miR-34a-5p BCL2 1.9 0 -2.02 0 miRNAWalker2 validate; miRTarBase -0.31 0 24565525; 23155233; 24444609; 20687223; 22623155; 24988056; 18803879; 19714243; 25053345; 20433755; 21399894; 22964582; 23862748 In vitro and in vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2;The miR-34a expression levels in cells after irradiation at 30 and 60 Gy were 0.17- and 18.7-times the BCL2 and caspase-9 expression levels respectively;Functional analyses further indicate that restoration of miR-34a inhibits B cell lymphoma-2 Bcl-2 protein expression to withdraw the survival advantage of these resistant NSCLC cells;Thus in PC3PR cells reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression; MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer;MiR 34a inhibits proliferation and migration of breast cancer through down regulation of Bcl 2 and SIRT1; In this study we aimed to determine the effect of miR-34a on the growth of breast cancer and to investigate whether its effect is achieved by targeting Bcl-2 and SIRT1; Bcl-2 and SIRT1 as the targets of miR-34a were found to be in reverse correlation with ectopic expression of miR-34a;Target analysis indicated that micro RNA miR-34a directly regulates Bcl-2 and miR-34a overexpression decreased Bcl-2 protein level in gastric cancer cells; We also found that luteolin upregulates miR-34a expression and downregulates Bcl-2 expression; Based on these results we can draw the conclusion that luteolin partly decreases Bcl-2 expression through upregulating miR-34a expression;miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making;Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2 suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells; Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal potentially via the direct modulation of downstream targets Bcl-2 and Notch implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination;Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may in part regulate response to docetaxel;For instance miR-34a up-regulation corresponded with a down-regulation of BCL2 protein; Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;MicroRNA 34a targets Bcl 2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment; HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore an inverse correlation is evident between the miR-34a level and Bcl-2 expression; Bioinformatics and luciferase reporter assays revealed that miR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation; Western blotting analysis and qRT-PCR confirmed that Bcl-2 is inhibited by miR-34a overexpression; Functional analyses indicated that the restoration of miR-34a reduced cell viability promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression
68 hsa-miR-140-5p BCL2L2 0.84 4.0E-5 -1.27 0 PITA; miRanda; miRNATAP -0.2 0 NA
69 hsa-miR-140-5p BCL9 0.84 4.0E-5 0.12 0.4783 MirTarget; PITA; miRanda; miRNATAP -0.16 8.0E-5 NA
70 hsa-miR-152-3p BHLHE41 -0.05 0.84435 -0.07 0.8646 MirTarget -0.5 0 NA
71 hsa-miR-194-5p BICD2 1.9 0 -0.46 0.01378 miRNATAP -0.16 0 NA
72 hsa-miR-34a-5p BIRC3 1.9 0 -1.15 0.00716 miRNAWalker2 validate -0.22 0.0078 NA
73 hsa-miR-34a-5p BMP1 1.9 0 0.19 0.45337 mirMAP -0.15 0.0018 NA
74 hsa-miR-152-3p BMP3 -0.05 0.84435 -0.54 0.56709 MirTarget -1.11 0 NA
75 hsa-miR-140-5p BMPR1A 0.84 4.0E-5 -0.77 0 miRanda -0.2 0 NA
76 hsa-miR-194-5p BNC1 1.9 0 -0.29 0.77524 MirTarget -1.14 0 NA
77 hsa-miR-34a-5p BNC2 1.9 0 -2.95 0 miRNATAP -0.8 0 NA
78 hsa-miR-194-5p BRMS1L 1.9 0 -0.51 0.00391 MirTarget -0.19 0 NA
79 hsa-miR-152-3p BTAF1 -0.05 0.84435 -0.16 0.37827 MirTarget -0.14 0.00019 NA
80 hsa-miR-140-5p BTBD7 0.84 4.0E-5 -0.3 0.03144 PITA -0.17 0 NA
81 hsa-miR-34a-5p C17orf51 1.9 0 -0.68 0.02254 mirMAP -0.25 1.0E-5 NA
82 hsa-miR-194-5p C1orf21 1.9 0 -1.51 0 mirMAP; miRNATAP -0.16 1.0E-5 NA
83 hsa-miR-34a-5p C1orf21 1.9 0 -1.51 0 mirMAP -0.22 0 NA
84 hsa-miR-34a-5p C3orf70 1.9 0 -2.6 0 miRNATAP -0.47 0 NA
85 hsa-miR-194-5p C6orf106 1.9 0 -0.16 0.26914 mirMAP -0.11 0 NA
86 hsa-miR-34a-5p C6orf106 1.9 0 -0.16 0.26914 miRNATAP -0.1 0.00011 NA
87 hsa-miR-152-3p CABP7 -0.05 0.84435 0.93 0.03157 MirTarget -0.26 0.0025 NA
88 hsa-miR-34a-5p CACHD1 1.9 0 -1.73 0 MirTarget -0.41 0 NA
89 hsa-miR-140-5p CACNA1C 0.84 4.0E-5 -2.53 0 PITA; miRNATAP -0.34 0.00027 NA
90 hsa-miR-34a-5p CACNA1C 1.9 0 -2.53 0 MirTarget -0.48 0 NA
91 hsa-miR-34a-5p CALD1 1.9 0 -2.47 0 miRNAWalker2 validate -0.73 0 NA
92 hsa-miR-34a-5p CAMK2B 1.9 0 0.67 0.19425 mirMAP -0.26 0.00749 NA
93 hsa-miR-140-5p CAMK2N1 0.84 4.0E-5 0.6 0.15571 PITA; miRanda -0.35 0.00036 NA
94 hsa-miR-34a-5p CAPN6 1.9 0 -3.48 0 miRNATAP -0.83 0 NA
95 hsa-miR-140-5p CASD1 0.84 4.0E-5 -0.65 0.0001 miRNAWalker2 validate -0.11 0.0058 NA
96 hsa-miR-140-5p CAST 0.84 4.0E-5 -0.66 0.00074 miRanda -0.22 0 NA
97 hsa-miR-140-5p CBR4 0.84 4.0E-5 -0.14 0.45863 miRanda -0.11 0.01278 NA
98 hsa-miR-140-5p CCDC146 0.84 4.0E-5 -0.73 0.00616 miRanda -0.19 0.00226 NA
99 hsa-miR-34a-5p CCDC50 1.9 0 -0.78 0 miRNATAP -0.18 0 NA
100 hsa-miR-152-3p CCDC71 -0.05 0.84435 0.3 0.02893 MirTarget -0.18 0 NA
101 hsa-miR-194-5p CD302 1.9 0 -1.68 0 mirMAP -0.15 0 NA
102 hsa-miR-34a-5p CD44 1.9 0 -0.8 0.04276 miRNAWalker2 validate; miRTarBase -0.28 0.00023 25572695; 24423412; 25551284; 25044638; 21240262; 26231042; 27497057; 23314380 The c-Myc and CD44 were confirmed as direct targets of miR-34a in EJ cell apoptosis induced by PRE;Furthermore we identified CD44 as being targeted by miR-34a in MIBC cells following cisplatin treatment and increased CD44 expression could efficiently reverse the effect of miR-34a on MIBC cell proliferation colongenic potential and chemosensitivity; Cisplatin-based chemotherapy induced demethylation of miR-34a promoter and increased miR-34a expression which in turn sensitized MIBC cells to cisplatin and decreased the tumorigenicity and proliferation of cancer cells that by reducing the production of CD44;MicroRNA 34a functions as an anti metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44; In this study we focus on it that microRNA-34a functions as an anti-metastatic microRNA and suppress angiogenesis in bladder cancer by directly targeting CD44; Our study defines a major metastasis and angiogenesis suppressive role for mir-34a a microRNA functions as a tumor suppressor in bladder cancer by directly targeting CD44 which would be helpful as a therapeutic approach to block bladder cancer metastasis;Nanocomplex-assisted delivery of miR-34a induces cell apoptosis and suppresses migration proliferation and tumor growth of breast cancer cells via targeting CD44 and a Notch-1-signaling pathway;The microRNA miR 34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44; We identified and validated CD44 as a direct and functional target of miR-34a and found that CD44 knockdown phenocopied miR-34a overexpression in inhibiting prostate cancer regeneration and metastasis;Registered report: the microRNA miR 34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44; Tumors with exogenous miR-34a showed reduced levels of CD44 expression Figure 4A and mutation of two putative miR-34a binding sites in the CD33 3' UTR partially abrogated signal repression in a luciferase assay Figure 4D;Nanovesicle mediated systemic delivery of microRNA 34a for CD44 overexpressing gastric cancer stem cell therapy; MicroRNA-34a miR-34a is a promising candidate for CD44 repression-based cancer therapy as it has been reported to inhibit proliferation metastasis and survival of CD44-positive CSCs; Here we used nanovesicles containing PLI/miR complexes NVs/miR to systemically deliver miR-34a and induce miR-34a-triggered CD44 suppression in orthotopically and subcutaneously implanted tumors in nude mice;miR 34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44; The ectopic overexpression of miR-34a significantly inhibited the migration and invasive ability of osteosarcoma cells by repressing the expression of CD44; These data suggest that miR-34a plays a tumor suppressor role in the metastasis of osteosarcoma cells by repressing the expression of CD44; Therefore it can be concluded that through the inhibition of CD44 expression levels miR-34a plays a significant role in the migration and invasion of osteosarcoma cells
103 hsa-miR-34a-5p CD47 1.9 0 -0.16 0.4808 miRNATAP -0.2 0 NA
104 hsa-miR-194-5p CDC42BPA 1.9 0 -1.41 0 mirMAP -0.17 0 NA
105 hsa-miR-34a-5p CDC5L 1.9 0 -0.01 0.91454 miRNAWalker2 validate -0.1 2.0E-5 NA
106 hsa-miR-194-5p CDH2 1.9 0 -0.37 0.51007 miRNAWalker2 validate; miRTarBase; miRNATAP -0.65 0 21845495; 20979124 The results of real-time PCR and western blot highlighted that miR-194 interacted with N-cadherin and negatively regulated its expression at the translational level;The overexpression of miR-194 in liver mesenchymal-like cancer cells reduced the expression of the mesenchymal cell marker N-cadherin and suppressed invasion and migration of the mesenchymal-like cancer cells both in vitro and in vivo
107 hsa-miR-140-5p CDH26 0.84 4.0E-5 0.92 0.14799 miRanda -0.3 0.04839 NA
108 hsa-miR-194-5p CDK14 1.9 0 -0.63 0.09517 MirTarget -0.34 0 NA
109 hsa-miR-152-3p CDK19 -0.05 0.84435 -0.08 0.56132 MirTarget -0.1 0.0001 NA
110 hsa-miR-34a-5p CDK6 1.9 0 -0.77 0.06479 miRNAWalker2 validate; miRTarBase; miRNATAP -0.52 0 21702042; 26104764 Molecular analyses identified Cdk6 and sirtuin SIRT-1 as being targeted by miR-34a in MI-TCC cells however inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization;The expression of microRNA 34a is inversely correlated with c MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients; We found significant inverse correlations between miR-34a and c-MET R = -0.316 P = 0.028 and CDK6 expression R = -0.4582 P = 0.004
111 hsa-miR-140-5p CDK8 0.84 4.0E-5 -0.22 0.28192 miRanda -0.15 0.00247 NA
112 hsa-miR-140-5p CDKL5 0.84 4.0E-5 -0.88 0.05367 miRanda -0.25 0.01826 NA
113 hsa-miR-34a-5p CDKN1C 1.9 0 -1.45 4.0E-5 miRNATAP -0.28 3.0E-5 NA
114 hsa-miR-34a-5p CDKN2C 1.9 0 0.23 0.43313 miRNAWalker2 validate -0.22 6.0E-5 NA
115 hsa-miR-34a-5p CDON 1.9 0 -2.61 0 miRNAWalker2 validate -0.69 0 NA
116 hsa-miR-34a-5p CEBPB 1.9 0 -0.38 0.12583 miRNAWalker2 validate -0.11 0.02632 NA
117 hsa-miR-34a-5p CELF2 1.9 0 -3.05 0 miRNATAP -0.63 0 NA
118 hsa-miR-194-5p CEP170 1.9 0 -0.11 0.58268 miRNATAP -0.15 0 NA
119 hsa-miR-34a-5p CEP170 1.9 0 -0.11 0.58268 miRNAWalker2 validate -0.25 0 NA
120 hsa-miR-140-5p CEP350 0.84 4.0E-5 -0.04 0.77047 MirTarget; miRanda -0.14 1.0E-5 NA
121 hsa-miR-140-5p CHD6 0.84 4.0E-5 -0.22 0.2394 miRanda -0.14 0.00233 NA
122 hsa-miR-194-5p CHD9 1.9 0 -0.8 1.0E-5 miRNATAP -0.13 0 NA
123 hsa-miR-140-5p CHIC1 0.84 4.0E-5 -1.03 0 miRanda -0.2 1.0E-5 NA
124 hsa-miR-34a-5p CHM 1.9 0 -0.35 0.02247 MirTarget -0.15 0 NA
125 hsa-miR-194-5p CIITA 1.9 0 -0.02 0.95968 mirMAP -0.21 0.0028 NA
126 hsa-miR-34a-5p CKAP5 1.9 0 0.47 0.00244 miRNAWalker2 validate -0.11 0.00011 NA
127 hsa-miR-194-5p CLIP4 1.9 0 -1.61 0 MirTarget -0.46 0 NA
128 hsa-miR-34a-5p CLOCK 1.9 0 -0.51 0.03689 MirTarget -0.2 1.0E-5 NA
129 hsa-miR-34a-5p CNST 1.9 0 -0.93 0 MirTarget -0.15 0 NA
130 hsa-miR-140-5p CNTN1 0.84 4.0E-5 -4.98 0 PITA; miRanda -0.87 1.0E-5 NA
131 hsa-miR-34a-5p CNTN2 1.9 0 -3.83 0 MirTarget; miRNATAP -0.54 0 NA
132 hsa-miR-34a-5p CNTNAP1 1.9 0 -1.47 0 MirTarget; miRNATAP -0.36 0 NA
133 hsa-miR-34a-5p CNTNAP2 1.9 0 -1.31 0.11505 miRNATAP -0.67 2.0E-5 NA
134 hsa-miR-34a-5p COL12A1 1.9 0 0.61 0.13434 MirTarget; miRNATAP -0.28 0.00031 NA
135 hsa-miR-34a-5p COL5A2 1.9 0 0.19 0.64093 MirTarget -0.41 0 NA
136 hsa-miR-34a-5p CORO1C 1.9 0 -1.12 0 MirTarget; miRNATAP -0.39 0 NA
137 hsa-miR-34a-5p CPEB2 1.9 0 -1.81 0 miRNATAP -0.29 0 NA
138 hsa-miR-34a-5p CPEB3 1.9 0 -1.3 0 miRNATAP -0.15 7.0E-5 NA
139 hsa-miR-34a-5p CR2 1.9 0 -1.53 0.0725 MirTarget -0.79 0 NA
140 hsa-miR-34a-5p CREB5 1.9 0 -2.28 0 miRNATAP -0.5 0 NA
141 hsa-miR-34a-5p CRY2 1.9 0 -1.68 0 MirTarget -0.17 0 NA
142 hsa-miR-140-5p CRYAB 0.84 4.0E-5 -3.8 0 miRanda -0.34 0.00352 NA
143 hsa-miR-140-5p CRYBG3 0.84 4.0E-5 -1.11 5.0E-5 miRanda -0.13 0.0437 NA
144 hsa-miR-140-5p CSDE1 0.84 4.0E-5 -0.72 0 miRanda -0.18 0 NA
145 hsa-miR-34a-5p CSF1R 1.9 0 -1.05 0.01797 MirTarget; miRNATAP -0.46 0 NA
146 hsa-miR-34a-5p CTCFL 1.9 0 0.39 0.13775 MirTarget -0.13 0.01043 NA
147 hsa-miR-34a-5p CTDSP2 1.9 0 -0.39 0.00969 miRNATAP -0.22 0 NA
148 hsa-miR-140-5p CTNNA1 0.84 4.0E-5 -0.28 0.01517 miRanda -0.12 3.0E-5 NA
149 hsa-miR-140-5p CTNNA3 0.84 4.0E-5 -1.94 0.00013 miRanda -0.25 0.03981 NA
150 hsa-miR-140-5p CTSF 0.84 4.0E-5 -1.38 0 miRanda -0.15 0.02452 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 NEUROGENESIS 124 1402 1.072e-17 4.988e-14
2 REGULATION OF CELL DIFFERENTIATION 125 1492 5.353e-16 1.033e-12
3 CELL DEVELOPMENT 121 1426 6.66e-16 1.033e-12
4 TISSUE DEVELOPMENT 122 1518 2.695e-14 3.135e-11
5 CELL PROJECTION ORGANIZATION 85 902 8.181e-14 7.613e-11
6 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 105 1275 4.956e-13 3.524e-10
7 CELLULAR COMPONENT MORPHOGENESIS 83 900 5.302e-13 3.524e-10
8 CENTRAL NERVOUS SYSTEM DEVELOPMENT 81 872 7.1e-13 4.13e-10
9 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 126 1672 9.796e-13 5.065e-10
10 NEURON DIFFERENTIATION 80 874 2.132e-12 9.918e-10
11 INTRACELLULAR SIGNAL TRANSDUCTION 118 1572 7.623e-12 3.224e-09
12 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 122 1656 1.097e-11 3.676e-09
13 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 87 1021 1.042e-11 3.676e-09
14 REGULATION OF CELL DEVELOPMENT 76 836 1.106e-11 3.676e-09
15 HEAD DEVELOPMENT 68 709 1.364e-11 4.232e-09
16 NEURON PROJECTION DEVELOPMENT 56 545 6.991e-11 2.033e-08
17 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 126 1784 7.895e-11 2.161e-08
18 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 91 1142 1.236e-10 3.194e-08
19 NEURON DEVELOPMENT 64 687 1.903e-10 4.66e-08
20 CELL PART MORPHOGENESIS 60 633 3.676e-10 8.551e-08
21 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 79 957 4.553e-10 1.009e-07
22 PROTEIN PHOSPHORYLATION 78 944 5.672e-10 1.2e-07
23 REGULATION OF PHOSPHORUS METABOLIC PROCESS 114 1618 8.535e-10 1.727e-07
24 REGULATION OF NEURON DIFFERENTIATION 53 554 2.94e-09 5.7e-07
25 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 64 740 3.796e-09 7.064e-07
26 ORGAN MORPHOGENESIS 69 841 7.974e-09 1.427e-06
27 POSITIVE REGULATION OF CELL COMMUNICATION 106 1532 9.684e-09 1.581e-06
28 FOREBRAIN DEVELOPMENT 39 357 1.073e-08 1.581e-06
29 REGULATION OF CELL PROJECTION ORGANIZATION 52 558 1.012e-08 1.581e-06
30 MUSCLE STRUCTURE DEVELOPMENT 44 432 1.047e-08 1.581e-06
31 NEURON PROJECTION MORPHOGENESIS 42 402 1.087e-08 1.581e-06
32 LOCOMOTION 84 1114 9.184e-09 1.581e-06
33 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 49 513 1.24e-08 1.749e-06
34 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 63 750 1.534e-08 2.099e-06
35 POSITIVE REGULATION OF NEURON DIFFERENTIATION 35 306 1.91e-08 2.469e-06
36 REGULATION OF CELL MORPHOGENESIS 51 552 1.867e-08 2.469e-06
37 POSITIVE REGULATION OF MOLECULAR FUNCTION 118 1791 2.04e-08 2.565e-06
38 REGULATION OF ACTIN FILAMENT BASED PROCESS 35 312 3.131e-08 3.834e-06
39 REGULATION OF PROTEIN MODIFICATION PROCESS 113 1710 3.655e-08 4.328e-06
40 ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY 22 141 3.72e-08 4.328e-06
41 POSITIVE REGULATION OF GENE EXPRESSION 114 1733 4.021e-08 4.563e-06
42 TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 60 724 5.541e-08 6.139e-06
43 SENSORY ORGAN DEVELOPMENT 46 493 7.034e-08 7.611e-06
44 CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION 38 368 7.434e-08 7.861e-06
45 CYTOSKELETON ORGANIZATION 66 838 8.095e-08 8.371e-06
46 POSITIVE REGULATION OF CELL DIFFERENTIATION 65 823 9.205e-08 9.311e-06
47 REGULATION OF HYDROLASE ACTIVITY 92 1327 9.451e-08 9.357e-06
48 REGULATION OF CELLULAR COMPONENT MOVEMENT 62 771 9.773e-08 9.474e-06
49 REGULATION OF TRANSPORT 116 1804 1.019e-07 9.676e-06
50 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 75 1008 1.045e-07 9.727e-06
51 REGULATION OF NEURON PROJECTION DEVELOPMENT 40 408 1.378e-07 1.257e-05
52 REGULATION OF MUSCLE CELL DIFFERENTIATION 22 152 1.469e-07 1.314e-05
53 POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION 33 303 1.56e-07 1.369e-05
54 NEURON PROJECTION GUIDANCE 26 205 1.685e-07 1.426e-05
55 PHOSPHORYLATION 86 1228 1.676e-07 1.426e-05
56 RESPONSE TO ENDOGENOUS STIMULUS 97 1450 2.2e-07 1.828e-05
57 NEURON MIGRATION 18 110 3.078e-07 2.513e-05
58 REGULATION OF GTPASE ACTIVITY 55 673 3.166e-07 2.54e-05
59 EPITHELIUM DEVELOPMENT 70 945 3.372e-07 2.559e-05
60 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 62 799 3.41e-07 2.559e-05
61 CELL MOTILITY 64 835 3.383e-07 2.559e-05
62 LOCALIZATION OF CELL 64 835 3.383e-07 2.559e-05
63 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 73 1004 3.802e-07 2.808e-05
64 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 122 1977 4.166e-07 3.028e-05
65 CARDIOVASCULAR SYSTEM DEVELOPMENT 61 788 4.616e-07 3.254e-05
66 CIRCULATORY SYSTEM DEVELOPMENT 61 788 4.616e-07 3.254e-05
67 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 93 1395 4.687e-07 3.255e-05
68 POSITIVE REGULATION OF RESPONSE TO STIMULUS 119 1929 6.032e-07 4.128e-05
69 MUSCLE ORGAN DEVELOPMENT 30 277 6.405e-07 4.319e-05
70 HEART DEVELOPMENT 42 466 6.62e-07 4.4e-05
71 POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 40 437 8.255e-07 5.41e-05
72 EAR DEVELOPMENT 24 195 8.675e-07 5.564e-05
73 REGULATION OF CELLULAR LOCALIZATION 86 1277 8.73e-07 5.564e-05
74 REGULATION OF MAPK CASCADE 53 660 8.914e-07 5.605e-05
75 POSITIVE REGULATION OF CELL DEVELOPMENT 42 472 9.266e-07 5.749e-05
76 NEGATIVE REGULATION OF CELL DIFFERENTIATION 50 609 9.614e-07 5.886e-05
77 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 112 1805 1.032e-06 6.239e-05
78 NEGATIVE REGULATION OF CELL COMMUNICATION 81 1192 1.314e-06 7.839e-05
79 TELENCEPHALON DEVELOPMENT 26 228 1.345e-06 7.919e-05
80 TAXIS 41 464 1.492e-06 8.679e-05
81 REGULATION OF CYTOPLASMIC TRANSPORT 42 481 1.513e-06 8.694e-05
82 MUSCLE TISSUE DEVELOPMENT 29 275 1.692e-06 9.486e-05
83 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 60 801 1.687e-06 9.486e-05
84 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 33 337 1.754e-06 9.6e-05
85 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 64 876 1.752e-06 9.6e-05
86 POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT 26 232 1.868e-06 0.0001011
87 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 72 1036 2.397e-06 0.0001268
88 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 72 1036 2.397e-06 0.0001268
89 NEGATIVE REGULATION OF GENE EXPRESSION 95 1493 2.662e-06 0.0001392
90 REGULATION OF MUSCLE SYSTEM PROCESS 23 195 3.051e-06 0.0001577
91 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 53 689 3.205e-06 0.0001639
92 EMBRYO DEVELOPMENT 64 894 3.435e-06 0.0001737
93 CEREBRAL CORTEX DEVELOPMENT 16 105 3.653e-06 0.0001828
94 FAT CELL DIFFERENTIATION 16 106 4.147e-06 0.0002053
95 ACTIN FILAMENT BASED PROCESS 39 450 4.272e-06 0.0002092
96 REGULATION OF CYTOSKELETON ORGANIZATION 42 502 4.472e-06 0.0002167
97 POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION 14 84 5.03e-06 0.0002388
98 EMBRYONIC MORPHOGENESIS 44 539 5.008e-06 0.0002388
99 POSITIVE REGULATION OF HYDROLASE ACTIVITY 64 905 5.111e-06 0.0002402
100 POSITIVE REGULATION OF CATALYTIC ACTIVITY 95 1518 5.323e-06 0.0002452
101 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 111 1848 5.303e-06 0.0002452
102 SKELETAL SYSTEM DEVELOPMENT 39 455 5.551e-06 0.0002532
103 RESPONSE TO OXYGEN CONTAINING COMPOUND 88 1381 6.089e-06 0.000275
104 RESPONSE TO GROWTH FACTOR 40 475 6.453e-06 0.0002887
105 REGULATION OF MEMBRANE POTENTIAL 32 343 6.939e-06 0.0003075
106 TISSUE MORPHOGENESIS 43 533 8.592e-06 0.0003772
107 REGULATION OF HOMEOSTATIC PROCESS 38 447 8.825e-06 0.0003838
108 TUBE DEVELOPMENT 44 552 9.151e-06 0.0003941
109 ENDOMEMBRANE SYSTEM ORGANIZATION 39 465 9.232e-06 0.0003941
110 PALLIUM DEVELOPMENT 19 153 1.032e-05 0.0004366
111 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 86 1360 1.048e-05 0.0004393
112 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 43 541 1.239e-05 0.0005101
113 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 43 541 1.239e-05 0.0005101
114 REGULATION OF SYSTEM PROCESS 41 507 1.312e-05 0.0005354
115 PROTEIN LOCALIZATION 107 1805 1.418e-05 0.0005736
116 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 93 1517 1.53e-05 0.0006138
117 POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 9 39 1.664e-05 0.0006618
118 EYE DEVELOPMENT 30 326 1.738e-05 0.0006852
119 STRIATED MUSCLE CELL DIFFERENTIATION 20 173 1.784e-05 0.0006977
120 GROWTH 35 410 1.815e-05 0.0007037
121 CELLULAR RESPONSE TO ACID CHEMICAL 20 175 2.113e-05 0.0008127
122 RHYTHMIC PROCESS 28 298 2.254e-05 0.0008597
123 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 71 1087 2.304e-05 0.0008715
124 NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 50 684 2.392e-05 0.0008977
125 REGULATION OF HEART CONTRACTION 23 221 2.427e-05 0.0009036
126 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 74 1152 2.688e-05 0.0009904
127 MODULATION OF SYNAPTIC TRANSMISSION 28 301 2.703e-05 0.0009904
128 GLAND MORPHOGENESIS 14 97 2.755e-05 0.001002
129 CELLULAR MACROMOLECULE LOCALIZATION 78 1234 2.813e-05 0.001014
130 CONNECTIVE TISSUE DEVELOPMENT 21 194 3.021e-05 0.001081
131 NEGATIVE REGULATION OF CELL DEVELOPMENT 28 303 3.046e-05 0.001082
132 IMMUNE SYSTEM DEVELOPMENT 44 582 3.331e-05 0.00115
133 RESPONSE TO EXTERNAL STIMULUS 106 1821 3.336e-05 0.00115
134 NEGATIVE REGULATION OF PHOSPHORYLATION 35 422 3.316e-05 0.00115
135 REGULATION OF MUSCLE ADAPTATION 11 63 3.284e-05 0.00115
136 REGULATION OF INTRACELLULAR TRANSPORT 46 621 3.662e-05 0.001253
137 CELL FATE COMMITMENT 23 227 3.714e-05 0.001261
138 MEMBRANE ASSEMBLY 7 25 3.825e-05 0.00129
139 REGULATION OF PROTEIN LOCALIZATION 63 950 4.33e-05 0.001449
140 REGULATION OF EMBRYONIC DEVELOPMENT 15 114 4.387e-05 0.001458
141 VENTRICULAR SYSTEM DEVELOPMENT 7 26 5.056e-05 0.001669
142 CELL PROJECTION ASSEMBLY 25 264 5.366e-05 0.001758
143 PLASMA MEMBRANE ORGANIZATION 21 203 5.903e-05 0.001921
144 LATERAL VENTRICLE DEVELOPMENT 5 12 6.037e-05 0.001951
145 MORPHOGENESIS OF AN EPITHELIUM 33 400 6.12e-05 0.001964
146 COGNITION 24 251 6.452e-05 0.002056
147 REGULATION OF CELL DEATH 88 1472 6.554e-05 0.002075
148 PEPTIDYL THREONINE MODIFICATION 9 46 6.75e-05 0.002122
149 REGULATION OF CELL PROLIFERATION 89 1496 7.067e-05 0.002207
150 CIRCADIAN REGULATION OF GENE EXPRESSION 10 57 7.15e-05 0.002218
151 MUSCLE CELL DIFFERENTIATION 23 237 7.255e-05 0.002229
152 RESPONSE TO OXIDATIVE STRESS 30 352 7.281e-05 0.002229
153 ACTIN FILAMENT BASED MOVEMENT 13 93 7.432e-05 0.00226
154 PEPTIDYL SERINE MODIFICATION 17 148 8.079e-05 0.002436
155 AXON EXTENSION 8 37 8.116e-05 0.002436
156 BIOLOGICAL ADHESION 66 1032 8.438e-05 0.002517
157 REGULATION OF PROTEIN KINASE B SIGNALING 15 121 8.798e-05 0.002608
158 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 71 1135 8.987e-05 0.002646
159 TUBE MORPHOGENESIS 28 323 9.373e-05 0.002743
160 GLIAL CELL DIFFERENTIATION 16 136 9.757e-05 0.002837
161 PROTEIN LOCALIZATION TO CELL PERIPHERY 17 151 0.0001038 0.003
162 SKELETAL MUSCLE ORGAN DEVELOPMENT 16 137 0.0001065 0.003059
163 REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 25 278 0.0001232 0.003516
164 CELLULAR RESPONSE TO NITROGEN COMPOUND 38 505 0.0001244 0.003531
165 REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION 12 85 0.0001265 0.003568
166 MEMBRANE BIOGENESIS 7 30 0.0001363 0.00382
167 MICROTUBULE CYTOSKELETON ORGANIZATION 29 348 0.0001411 0.003932
168 NEGATIVE REGULATION OF CELL DEATH 57 872 0.0001465 0.004059
169 BONE DEVELOPMENT 17 156 0.000155 0.004268
170 DEVELOPMENTAL GROWTH 28 333 0.0001572 0.004304
171 BONE CELL DEVELOPMENT 6 22 0.0001637 0.004404
172 REGULATION OF ORGANELLE ORGANIZATION 72 1178 0.0001622 0.004404
173 SUBPALLIUM DEVELOPMENT 6 22 0.0001637 0.004404
174 REGULATION OF PHOSPHATASE ACTIVITY 15 128 0.0001667 0.004445
175 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 32 404 0.0001672 0.004445
176 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 87 1492 0.0001696 0.004483
177 OSSIFICATION 23 251 0.000172 0.004521
178 ESTABLISHMENT OF CELL POLARITY 12 88 0.0001772 0.004633
179 MYELOID CELL DIFFERENTIATION 19 189 0.0001901 0.004943
180 STEM CELL DIFFERENTIATION 19 190 0.0002036 0.005264
181 NEURON PROJECTION EXTENSION 9 53 0.000212 0.00545
182 REGULATION OF CELLULAR COMPONENT BIOGENESIS 51 767 0.0002172 0.005541
183 RESPONSE TO REACTIVE OXYGEN SPECIES 19 191 0.0002179 0.005541
184 ESTABLISHMENT OF LOCALIZATION IN CELL 95 1676 0.0002293 0.005799
185 CARTILAGE DEVELOPMENT 16 147 0.000243 0.006048
186 MICROTUBULE BASED PROCESS 38 522 0.0002425 0.006048
187 ENSHEATHMENT OF NEURONS 12 91 0.0002444 0.006048
188 AXON ENSHEATHMENT 12 91 0.0002444 0.006048
189 GLAND DEVELOPMENT 31 395 0.000247 0.006052
190 REGULATION OF INSULIN RECEPTOR SIGNALING PATHWAY 8 43 0.0002471 0.006052
191 REGULATION OF METAL ION TRANSPORT 27 325 0.0002484 0.006052
192 ODONTOGENESIS 13 105 0.0002587 0.00627
193 POSITIVE REGULATION OF CELL GROWTH 16 148 0.0002627 0.006334
194 VASCULATURE DEVELOPMENT 35 469 0.0002657 0.006373
195 RESPONSE TO HORMONE 57 893 0.0002697 0.006435
196 REGULATION OF STRIATED MUSCLE CONTRACTION 11 79 0.0002713 0.006441
197 REGULATION OF MYELOID CELL APOPTOTIC PROCESS 6 24 0.000276 0.00652
198 POSITIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY 5 16 0.0002917 0.006786
199 MEGAKARYOCYTE DEVELOPMENT 5 16 0.0002917 0.006786
200 STRIATUM DEVELOPMENT 5 16 0.0002917 0.006786
201 CELL GROWTH 15 135 0.0003005 0.006957
202 SINGLE ORGANISM CELLULAR LOCALIZATION 57 898 0.0003103 0.007148
203 NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 23 262 0.0003207 0.007351
204 CELLULAR COMPONENT ASSEMBLY INVOLVED IN MORPHOGENESIS 22 246 0.000332 0.007572
205 SINGLE ORGANISM BEHAVIOR 30 384 0.0003337 0.007573
206 REGULATION OF TRANSPORTER ACTIVITY 19 198 0.0003451 0.007795
207 CIRCADIAN RHYTHM 15 137 0.0003527 0.007927
208 REGULATION OF CELLULAR PROTEIN LOCALIZATION 39 552 0.0003672 0.008213
209 REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING 15 138 0.0003815 0.008493
210 BEHAVIOR 37 516 0.0003892 0.008583
211 CELLULAR RESPONSE TO OXIDATIVE STRESS 18 184 0.0003876 0.008583
212 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 39 554 0.0003942 0.008652
213 ANATOMICAL STRUCTURE ARRANGEMENT 5 17 0.0003998 0.008693
214 MYELIN ASSEMBLY 5 17 0.0003998 0.008693
215 MAINTENANCE OF LOCATION IN CELL 12 96 0.0004041 0.008706
216 CARDIOCYTE DIFFERENTIATION 12 96 0.0004041 0.008706
217 REGULATION OF ION HOMEOSTASIS 19 201 0.0004169 0.008939
218 REGULATION OF EPITHELIAL CELL PROLIFERATION 24 285 0.0004418 0.009431
219 POSITIVE REGULATION OF AXON EXTENSION 7 36 0.0004545 0.009656
220 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 42 616 0.0004632 0.009796
221 POSITIVE REGULATION OF DEPHOSPHORYLATION 8 47 0.0004661 0.009814
222 POSITIVE REGULATION OF DEVELOPMENTAL GROWTH 16 156 0.000476 0.009977
NumGOOverlapSizeP ValueAdj. P Value
1 ENZYME BINDING 133 1737 6.055e-14 5.625e-11
2 CYTOSKELETAL PROTEIN BINDING 71 819 4.565e-10 2.121e-07
3 RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING 59 629 7.753e-10 2.401e-07
4 BETA CATENIN BINDING 18 84 3.857e-09 8.958e-07
5 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 89 1199 6.764e-09 1.257e-06
6 KINASE BINDING 55 606 9.504e-09 1.472e-06
7 ACTIN BINDING 41 393 1.697e-08 2.252e-06
8 KINASE ACTIVITY 67 842 4.348e-08 5.049e-06
9 PROTEIN KINASE ACTIVITY 55 640 6.117e-08 5.958e-06
10 TRANSCRIPTION FACTOR BINDING 48 524 6.414e-08 5.958e-06
11 REGULATORY REGION NUCLEIC ACID BINDING 65 818 7.353e-08 6.21e-06
12 ACTIVATING TRANSCRIPTION FACTOR BINDING 13 57 2.604e-07 2.016e-05
13 TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 34 328 3.293e-07 2.353e-05
14 PROTEIN SERINE THREONINE KINASE ACTIVITY 41 445 5.072e-07 3.366e-05
15 MACROMOLECULAR COMPLEX BINDING 92 1399 9.815e-07 5.735e-05
16 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 71 992 9.877e-07 5.735e-05
17 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING 32 315 1.135e-06 6.202e-05
18 SEQUENCE SPECIFIC DNA BINDING 71 1037 4.758e-06 0.0002456
19 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY 12 64 6.754e-06 0.0003302
20 DOUBLE STRANDED DNA BINDING 56 764 7.181e-06 0.0003336
21 MOLECULAR FUNCTION REGULATOR 86 1353 8.618e-06 0.0003813
22 PROTEIN DOMAIN SPECIFIC BINDING 48 624 9.354e-06 0.000395
23 GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY 29 303 1.141e-05 0.0004489
24 TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING 24 226 1.16e-05 0.0004489
25 RAS GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY 24 228 1.345e-05 0.0004999
26 TRANSMEMBRANE RECEPTOR PROTEIN KINASE ACTIVITY 13 81 1.663e-05 0.0005941
27 SMAD BINDING 12 72 2.364e-05 0.0007947
28 ADENYL NUCLEOTIDE BINDING 92 1514 2.395e-05 0.0007947
29 TRANSCRIPTION COFACTOR BINDING 7 24 2.851e-05 0.0009133
30 GTPASE BINDING 27 295 4.958e-05 0.001535
31 CHROMATIN BINDING 35 435 6.153e-05 0.001786
32 RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING 14 104 6.067e-05 0.001786
33 RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING 8 36 6.588e-05 0.001855
34 PHOSPHATASE BINDING 18 162 7.799e-05 0.002128
35 CORE PROMOTER PROXIMAL REGION DNA BINDING 31 371 8.019e-05 0.002128
36 PROTEIN COMPLEX BINDING 61 935 9.076e-05 0.002342
37 RIBONUCLEOTIDE BINDING 105 1860 0.0001221 0.003067
38 TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING 42 588 0.0001754 0.004288
39 PROTEIN KINASE A BINDING 8 42 0.0002083 0.004962
40 TUBULIN BINDING 24 273 0.0002349 0.005456
41 CALCIUM ION BINDING 47 697 0.0002786 0.006312
42 UBIQUITIN LIKE PROTEIN LIGASE BINDING 23 264 0.0003575 0.007907
NumGOOverlapSizeP ValueAdj. P Value
1 CELL JUNCTION 105 1151 6.163e-16 3.599e-13
2 CYTOSKELETON 146 1967 3.389e-14 9.897e-12
3 ANCHORING JUNCTION 53 489 3.179e-11 5.4e-09
4 MEMBRANE REGION 92 1134 3.699e-11 5.4e-09
5 ACTIN CYTOSKELETON 49 444 9.563e-11 1.117e-08
6 CELL PROJECTION 125 1786 1.711e-10 1.666e-08
7 SYNAPSE 66 754 1.312e-09 1.094e-07
8 PLASMA MEMBRANE REGION 76 929 1.499e-09 1.094e-07
9 CELL LEADING EDGE 40 350 1.888e-09 1.225e-07
10 CELL SUBSTRATE JUNCTION 43 398 2.639e-09 1.472e-07
11 NEURON PROJECTION 76 942 2.772e-09 1.472e-07
12 CYTOSKELETAL PART 102 1436 4.936e-09 2.402e-07
13 POSTSYNAPSE 39 378 5.121e-08 2.3e-06
14 SYNAPSE PART 53 610 7.508e-08 3.132e-06
15 CYTOPLASMIC REGION 32 287 1.401e-07 5.456e-06
16 CELL CELL JUNCTION 38 383 2.09e-07 7.628e-06
17 EXCITATORY SYNAPSE 25 197 2.869e-07 9.855e-06
18 NEURON PART 87 1265 3.089e-07 1.002e-05
19 MICROTUBULE CYTOSKELETON 76 1068 5.013e-07 1.541e-05
20 CELL CORTEX 27 238 9.364e-07 2.734e-05
21 CELL CORTEX PART 18 119 1.021e-06 2.8e-05
22 CONTRACTILE FIBER 25 211 1.055e-06 2.8e-05
23 LAMELLIPODIUM 22 172 1.283e-06 3.257e-05
24 CORTICAL ACTIN CYTOSKELETON 12 58 2.28e-06 5.549e-05
25 SOMATODENDRITIC COMPARTMENT 51 650 2.809e-06 6.562e-05
26 APICAL JUNCTION COMPLEX 18 128 3.003e-06 6.745e-05
27 MEMBRANE MICRODOMAIN 29 288 4.261e-06 9.215e-05
28 DENDRITE 39 451 4.504e-06 9.393e-05
29 CELL PROJECTION PART 65 946 1.089e-05 0.0002192
30 MAIN AXON 11 58 1.454e-05 0.000283
31 SYNAPTIC MEMBRANE 26 261 1.596e-05 0.0003006
32 I BAND 16 121 2.316e-05 0.0004227
33 MICROTUBULE 34 405 3.35e-05 0.0005929
34 COSTAMERE 6 19 6.592e-05 0.001132
35 CORTICAL CYTOSKELETON 12 81 7.858e-05 0.001311
36 SARCOPLASMIC RETICULUM MEMBRANE 8 38 9.926e-05 0.00161
37 GLYCOPROTEIN COMPLEX 6 21 0.0001232 0.001944
38 MICROTUBULE ORGANIZING CENTER 44 623 0.0001593 0.002448
39 CELL CELL CONTACT ZONE 10 64 0.0001954 0.002926
40 NODE OF RANVIER 5 15 0.0002073 0.003026
41 CELL CELL ADHERENS JUNCTION 9 54 0.0002456 0.003498
42 AXON 32 418 0.0003075 0.004261
43 A BAND 7 34 0.0003137 0.004261
44 FILOPODIUM 12 94 0.000332 0.004309
45 SARCOPLASM 10 68 0.0003254 0.004309
46 PHOSPHATASE COMPLEX 8 48 0.0005402 0.006712
47 POSTSYNAPTIC MEMBRANE 19 205 0.0005325 0.006712
48 APICAL PLASMA MEMBRANE 24 292 0.0006252 0.007606
49 INTERCALATED DISC 8 51 0.0008212 0.009788

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 MAPK_signaling_pathway_hsa04010 30 295 2.388e-06 7.557e-05
2 Hippo_signaling_pathway_hsa04390 20 154 3.044e-06 7.557e-05
3 Adherens_junction_hsa04520 13 72 4.36e-06 7.557e-05
4 Rap1_signaling_pathway_hsa04015 21 206 7.304e-05 0.0009496
5 Gap_junction_hsa04540 12 88 0.0001772 0.001763
6 Wnt_signaling_pathway_hsa04310 16 146 0.0002247 0.001763
7 Regulation_of_actin_cytoskeleton_hsa04810 20 208 0.0002373 0.001763
8 Focal_adhesion_hsa04510 19 199 0.0003677 0.00239
9 HIF_1_signaling_pathway_hsa04066 12 100 0.0005886 0.003401
10 PI3K_Akt_signaling_pathway_hsa04151 27 352 0.0008555 0.004449
11 Autophagy_animal_hsa04140 13 128 0.001711 0.008087
12 Calcium_signaling_pathway_hsa04020 16 182 0.002445 0.01003
13 Sphingolipid_signaling_pathway_hsa04071 12 118 0.002508 0.01003
14 Hippo_signaling_pathway_multiple_species_hsa04392 5 29 0.005179 0.01747
15 Ras_signaling_pathway_hsa04014 18 232 0.00521 0.01747
16 Phospholipase_D_signaling_pathway_hsa04072 13 146 0.005376 0.01747
17 Phosphatidylinositol_signaling_system_hsa04070 10 99 0.005833 0.01784
18 ErbB_signaling_pathway_hsa04012 9 85 0.006421 0.01855
19 mTOR_signaling_pathway_hsa04150 13 151 0.007098 0.01943
20 Apelin_signaling_pathway_hsa04371 12 137 0.00831 0.02134
21 AMPK_signaling_pathway_hsa04152 11 121 0.008617 0.02134
22 Hedgehog_signaling_pathway_hsa04340 6 47 0.01019 0.02322
23 Oocyte_meiosis_hsa04114 11 124 0.01027 0.02322
24 cGMP_PKG_signaling_pathway_hsa04022 13 163 0.01302 0.02821
25 FoxO_signaling_pathway_hsa04068 11 132 0.01587 0.033
26 Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 11 139 0.02241 0.04483
27 Cellular_senescence_hsa04218 12 160 0.02555 0.04921
28 Cell_adhesion_molecules_.CAMs._hsa04514 11 145 0.02944 0.05468
29 Tight_junction_hsa04530 12 170 0.03821 0.06852
30 Notch_signaling_pathway_hsa04330 5 48 0.04051 0.07022
31 ECM_receptor_interaction_hsa04512 7 82 0.0437 0.07331
32 TGF_beta_signaling_pathway_hsa04350 7 84 0.04873 0.07918
33 cAMP_signaling_pathway_hsa04024 13 198 0.05185 0.08171
34 Jak_STAT_signaling_pathway_hsa04630 11 162 0.05762 0.08614
35 Cell_cycle_hsa04110 9 124 0.05798 0.08614
36 Endocytosis_hsa04144 14 244 0.1064 0.1537
37 TNF_signaling_pathway_hsa04668 7 108 0.1367 0.1922
38 Apoptosis_multiple_species_hsa04215 3 33 0.141 0.193
39 VEGF_signaling_pathway_hsa04370 4 59 0.2051 0.2734
40 Cytokine_cytokine_receptor_interaction_hsa04060 13 270 0.2743 0.3566
41 Apoptosis_hsa04210 7 138 0.3064 0.3886
42 NF_kappa_B_signaling_pathway_hsa04064 5 95 0.3237 0.4007
43 Necroptosis_hsa04217 7 164 0.4745 0.5738
44 ABC_transporters_hsa02010 2 45 0.5368 0.6344
45 Peroxisome_hsa04146 3 83 0.6437 0.7438
46 Lysosome_hsa04142 4 123 0.7228 0.803
47 p53_signaling_pathway_hsa04115 2 68 0.7568 0.8198
48 Neuroactive_ligand_receptor_interaction_hsa04080 7 278 0.9272 0.9462

Quest ID: 6f7829c07ab8cf567e39cce27ec6a67f